A Study of Apatinib Mesylate (YN968D1) 1,000mg in Gastric Cancer Patient Failed to Standard Treatment

NCT02711969 · clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
6
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Bukwang Pharmaceutical